WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced the first presentation of findings with the
Company's CD37-targeting ADC, IMGN529, in combination with the
CD20-targeting antibody, rituximab (Rituxan®), in preclinical
assessments. These data are being presented in a poster at the 13th
International Conference on Malignant Lymphoma taking place in Lugano,
Switzerland (abstract #P-274).
Among the findings being presented are:
IMGN529 exhibits strong synergy with rituximab and other
CD20-targeting antibodies in cell lines representative of an array of
non-Hodgkin lymphoma (NHL) subtypes, including both GCB and ABC
diffuse large B-cell lymphoma (DLBCL);
Consistent with the in vitro findings, the combination of
IMGN529 and rituximab was highly active against DLBCL models in vivo;
Synergy also was seen in vitro in a model representative
of "double hit" lymphoma, a particularly difficult-to-treat type of
DLBCL characterized by deregulation of two different genes, BCL2 (or
BCL6) and MYC; and
Both IMGN529's antibody component and its DM1 payload contributed to
its synergistic activity with rituximab.
"Rituximab is a standard of care in the treatment of B-cell
malignancies, and thus it is highly exciting that IMGN529 and rituximab
demonstrate synergistic activity in combination in these models,"
commented Dr. Charles Morris, EVP and Chief Development Officer of
ImmunoGen. "We plan to initiate clinical testing of IMGN529 in
combination with rituximab later this year to assess the potential
benefit of such a regimen for patients with DLBCL."
IMGN529 is currently in Phase I clinical testing for the treatment of
NHL, used as a single agent in patients with heavily pre-treated
disease. It has demonstrated encouraging evidence of activity,
particularly for patients with relapsed/refractory DLBCL.1
Later this year, ImmunoGen plans to begin assessing IMGN529 used in
combination with rituximab for the treatment of relapsed/refractory
DLBCL in addition to assessing it as a single agent in DLBCL and chronic
lymphocytic leukemia disease-specific patient populations.
IMGN529 is a CD37-targeting ADC created by ImmunoGen for the treatment
of B-cell malignancies. It consists of a CD37-binding antibody with one
of the Company's potent cancer cell-killing agents, DM1, attached. The
antibody serves to deliver the DM1 specifically to B cells to kill them
and, based on preclinical research, also contributes anticancer activity.
About Diffuse Large B-cell Lymphoma (DLBCL)
More than 70,000 people will be diagnosed with non-Hodgkin lymphoma
(NHL) in the US in 2014.2 DLBCL is an aggressive lymphoma
that represents approximately one third of the new NHL cases diagnosed
annually.2 GCB, or Germinal Center B-cell like, and ABC, or
Activated B-cell like, are prevalent sub-types of DLBCL which can differ
markedly in their responses to treatment.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells. The Company utilizes
its ADC technology with its antibodies to create ImmunoGen product
candidates and also out-licenses limited rights to use its technology to
other companies. Roche's Kadcyla® is the first marketed
product with ImmunoGen's ADC technology. More information about the
Company can be found at www.immunogen.com.
Rituxan® and Kadcyla® are registered trademarks of
their respective owners.
1American Society of Hematology annual meeting 2014; abstract
2American Cancer Society (2014), Cancer Facts & Figures.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including IMGN529, including risks related to preclinical and clinical
studies, their timings and results. A review of these risks can be found
in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June
30, 2014 and other reports filed with the Securities and Exchange
View source version on businesswire.com: http://www.businesswire.com/news/home/20150617005195/en/
Carol Hausner, 781-895-0600
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media